IL2 and neoplasm: In the group of animals where the AJ-IL2/IL12 vaccine was used to treat established tumours, a significant reduction in tumour growth was also observed at 12 days (81±55 mm3) compared with RPMI-treated controls (P<0.001) (Figure 3).